Browse: Departments Dates Agencies
SUBJECT CATEGORY: Implantation or Injectable Dosage Form New Animal Drugs; Oxytetracycline Solution
DOCUMENT SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Norbrook Laboratories, Ltd. The supplemental NADA provides for changing scientific nomenclature for a bovine pathogen on labeling for 300 milligrams per milliliter (mg/mL) strength oxytetracycline injectable solution.
SUMMARY: Implantation or Injectable Dosage Form New Animal Drugs; Oxytetracycline Solution,
Approval of this supplemental NADA did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.
The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801808.
List of Subjects in 21 CFR Part 522
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:
PART 522IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 522 continues to read as follows:
Authority: 21 U.S.C. 360b.
2. In Sec. 522.1660, revise the section heading to read as follows: Sec. 522.1660 Oxytetracycline injectable dosage forms.
3. In Sec. 522.1660a, revise the section heading to read as follows:
Sec. 522.1660a Oxytetracycline solution, 200 milligrams/milliliter. Sec. 522.1660b [Amended]
4. In Sec. 522.1660b, in the section heading, remove ``injection, 300
milligram/milliliter'' and in its place add ``solution, 300 milligrams/
milliliter''; in paragraph (e)(1)(i)(A), remove ``Haemophilus spp.''
and in its place add ``Histophilus spp.''; and in the fourth sentence in paragraph (e)(1)(ii), remove ``in cattle''.
Dated: March 6, 2008.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. E85598 Filed 31908; 8:45 am]
BILLING CODE 416001S
FOR FURTHER INFORMATION CONTACT Joan C. Gotthardt, Center for
Veterinary Medicine (HFV130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 2402768342, email:
joan.gotthardt@fda.hhs.gov.
14 CFR Part 39 40 CFR Part 52 14 CFR Part 71 33 CFR Part 165 26 CFR Part 1 50 CFR Part 679 33 CFR Part 117 40 CFR Part 180 44 CFR Part 67 50 CFR Part 17 47 CFR Part 73 50 CFR Part 648 14 CFR Part 97 33 CFR Part 100 40 CFR Part 63 50 CFR Part 622 26 CFR Part 301 39 CFR Part 111 44 CFR Part 65 40 CFR Parts 52 and 81 40 CFR Part 271 14 CFR Part 23 47 CFR Part 76 40 CFR Part 300 21 CFR Part 522 50 CFR Part 660 50 CFR Part 229 47 CFR Part 64 7 CFR Part 301 14 CFR Part 25